High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study.

Barnaby F FlowerLeanne McCabeChau Le NgocHung Le ManhPhuong Le ThanhThuan Dang TrongThu Vo ThiHang Vu Thi KimThanh Nguyen TatDao Phan Thi HongAn Nguyen Thi ChauTan Dinh ThiNga Tran Thi TuyetJoel TarningCherry KingsleyEvelyne KestelynSarah L PettGuy ThwaitesVinh Chau Nguyen VanDavid SmithEleanor BarnesM Azim AnsariHugo C TurnerMotiur RahmanAnn Sarah WalkerJeremy N DayGraham S Cooke

Published in: Open forum infectious diseases (2021)

Prescribing 12 weeks of SOF/DCV results in excellent cure rates in this population. These data support the removal of costly genotyping in countries where genotype 3 prevalence is <5%, in keeping with World Health Organization guidelines. NS5A resistance-associated mutations in isolation do not affect efficacy of SOF/DCV therapy. Wider evaluation of response-guided therapy is warranted.

Keyphrases

hepatitis c virus
liver fibrosis
human immunodeficiency virus
risk factors
gestational age
genome wide
high throughput
electronic health record
emergency department
big data
gene expression
machine learning
single cell
deep learning
zika virus
dna methylation